ClearPoint Neuro, Inc. (CLPT) Stock

ClearPoint Neuro, Inc. (CLPT) is a Healthcare stock trading at $15.19 (as of 2026-08-20), with a market capitalization of $463.36M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

ClearPoint Neuro, Inc. is a U.S. medical device company that develops and commercializes systems for minimally invasive brain procedures guided by direct and intra-procedural MRI. Its products include the ClearPoint system and an MRI-based Neuro Navigation suite, serving clinical users performing procedures such as deep brain stimulation electrode insertion, biopsies, and image-guided delivery of therapies.

Understand ClearPoint Neuro, Inc.: how it makes money

ClearPoint Neuro develops and commercializes minimally invasive brain surgery platforms under direct and intra-procedural MRI guidance, including the ClearPoint system and MRI navigation (and related product and service offerings) that generate revenue through product and related revenue lines.

With gross margin reported at 64.0% but an operating margin of -69.9%, the profit model depends on scaling revenue sufficiently fast relative to operating expenses, so progress in product adoption and procedure activity is critical to moving losses toward profitability.

Revenue by segment (latest quarter)
Product	$0.0B
Biologics	$0.0B
CapitalEquip+Svc	$0.0B
Airflow Disposable	$0.0B
Service+Other	$0.0B

Business quality (Weak): The company has adoption and clinical-trial activity metrics (installed base, active sites, trials, partners), but the latest quarter shows effectively no reported revenue and a large operating loss, making near-term financial visibility a key constraint.

Bull case

Broad installed footprint: The company reports an Activated Installed Base (Global Centers) of 175 and Active Sites Using ClearPoint Technology of 175.
Ongoing clinical and partner momentum: It reports Existing Clinical Trials of 25, Active Clinical Trials of 25, and Active Biopharma Partners of 60.
Procedure activity supports utilization: Functional Neurosurgery Navigation Cases Supported is 227, and PRISM Neural Laser Therapy System Additional Cohort Patients Enrolled is 10.

Bear case

Near-zero reported revenue in the latest quarter: Total revenue is reported as 0.0B for the period ending 2026-03-31, and many revenue categories in the candidate breakdown are 0.0B.
Large operating loss: Operating margin is reported at -69.9%, indicating substantial operating expense relative to revenue.
Execution risk tied to trials and adoption: Key operating metrics include clinical trials, biopharma partners, and new customer activations, so commercialization progress depends on converting these programs into sustained revenue.

Valuation — source: SEC EDGAR (first-party)
Price	$15.19
Market Cap	$463.36M
Price / Book	43.00
Price / Sales	10.53
FCF Yield	-7.1%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$36.97M
Net Margin	-69.1%
Revenue Growth (YoY)	17.8%
EPS Growth (YoY)	28.6%
FCF Growth (YoY)	165.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	0.98 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.6
Industry P/E (Medical Equipment)	32.9

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($24.17M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Medical Equipment
CEO	Joseph Michael Burnett
Employees	115
Country	US
IPO Date	2012-05-22

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.